1Di Marco V, Lo lacono O, Camms C, et al. The long-term course of chronic hepatitis B. Hepatology,1999; 30:257-264
2Liaw YF, Tai DI, Chu CM,Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology, 1988; 8:493-496
3Fattovich G, Brollo L,Giustina G, et al. Natural hitory and pronostic factors for chronic hepatitis type B. Gut, 1991: 32(3): 294-298
4Liaw YF, Sheen IS, Chen TJ, et al. Incidence,determinants, and significance of delayed clearance of serum HbsAg in chronic hepatitis B virus infection: a prospective study. Hepatology,1991; 13:627-631
5Christensen E, Schliehting P, Fauerholdt L, et al Prognostic value of Child-Turcotte criteria in medically treated cirrhosis.Hepatology,1984; 4: 430-435
6De Jongh FE, Janssen HL, De Man Ra, et al. Survival and prognostic indicators in hepatitis B surface antigen positive cirrhosis of liver. Gastroenterology, 1992: 103:(5): 1603-1635
7Hoofnagle JH, Di Bisceglie AM, waggoner JG, Park Y.Interferon alfa for patients with clinically apparent cirrhosis due to chronis hepatitis B. Gastroenterology,1993; 104: 1116-1121
8Perrillo R, Tamburro C, Regenstein F, et al. Low-dose,titerable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus.Gastroenterology, 1995; 109:908-916
9Villeneuve JP, Condreay LD, Willems B, et al.Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology, 2000;31: 207-210
10Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis Binfection. J Hepatol,2000; 33.. 301-307
